Centroflora CMS

Centroflora CMS is a global leader in the manufacturing of plant-based Active Pharmaceutical Ingredients (APIs) and a specialized CDMO. The company was established as a strategic partnership between the Brazilian Centroflora Group and the Swiss company CMS Pharma. It specializes in the extraction, isolation, and purification of high-potency alkaloids, including pilocarpine, scopolamine, and atropine. A major milestone for the company was the 2018 acquisition of Boehringer Ingelheim's alkaloid business, which solidified its position as a top-tier global supplier. Centroflora CMS operates state-of-the-art GMP-certified facilities in both Brazil and Switzerland, ensuring a secure and sustainable supply chain from field to pharmacy. Their services range from custom botanical extraction to the development of complex small-molecule APIs for the pharmaceutical industry.